Virtual MOUD Doesn't Expand Access. That's Not a Failure — It's the Map.
Peterson Health Technology Institute evaluated 16 virtual opioid-use-disorder solutions. They substitute for in-person care effectively. They do not enroll new patients. The 'navigation gap' between people who need treatment and people in treatment is the unmet need.
Virtual MOUD Doesn’t Expand Access. That’s Not a Failure — It’s the Map.
The Peterson Health Technology Institute (PHTI) assessment of 16 virtual opioid-use-disorder solutions — Affect, Aware, Better Life Partners, Bicycle Health, Boulder Care, CHESS, DynamiCare, Eleanor, Groups Recover Together, Ophelia, Pelago, PursueCare, Q2i, Wayspring, WEconnect, Workit Health — returned a clean and unsentimental finding. Virtual MOUD is as effective as in-person care. Mean retention: 150 days virtual vs 137 days in-person, or roughly 13 additional days over a 6-month window. There is no evidence that these solutions reduce overall cost of care.
The harder finding: the virtual MOUD companies are not enrolling first-time treatment seekers. Their access statistics mirror the national averages for in-person providers. They are not the on-ramp; they are a parallel road for people who were already going to get on the highway.
That isn’t a failure of the virtual MOUD model. It is the map of what the next chapter has to be.
If 48.5 million Americans have a substance use disorder and only roughly 15% receive any treatment, the unmet need is not better delivery for the people already navigating the system — it is the navigation layer for the people who never make it that far. Insurance verification, geographic match, clinical pathway, family support, peer connection: the literature is unambiguous that the friction in the months before a first appointment is where most people fall out of the funnel. None of the 16 PHTI-evaluated companies addresses that layer; all of them assume it.
Why this matters for people in recovery
If you, or someone you love, is at the very beginning of looking for help — not yet ready to call a clinic, not sure what kind of treatment fits, not sure what your insurance covers — you are exactly the person the existing virtual MOUD market doesn’t reach. That is also why navigation services like Rize exist. The right next step is rarely the same as the available next step, and figuring out which is which is the whole job.
988 Suicide & Crisis Lifeline: Call or text 988. SAMHSA National Helpline: 1-800-662-HELP (4357) — free, confidential, 24/7.
Sources Cited
- 01.B
- 02.B
- 03.B
Filed Under
treatmenttrendspolicy
Continue reading
More from this section
Relationship between attentional bias and psychological craving in methamphetamine use disorder
There's no FDA-approved medication for methamphetamine addiction. A dual-target TMS trial enrolling in 2026 targets the MPFC and DPFC simultaneously — the two brain regions most compromised by chronic stimulant use. Here's the science behind the approach.
Technology & InnovationAn AI Can Now Diagnose Addiction With 83% Accuracy. The Treatment System Still Can't Keep Up.
University of Cincinnati researchers built an AI that diagnoses substance use disorder with 83% accuracy using behavioral economics tools. The harder problem is what happens after the diagnosis.
Technology & InnovationOzempic for Addiction? The Science Is Catching Up to the Headlines
GLP-1 drugs like semaglutide show 50-56% lower AUD risk in a 2024 Nature study, with VA data confirming effects across 5+ substance classes. Clinical trials now running for opioid and cocaine use disorder.